| Officer | Age | In this role | Source |
|---|---|---|---|
|
Jan Møller Mikkelsen
Also a director
President, Chief Executive Officer and Board Member
|
66 |
Since 2007
19 years
|
|
|
Scott T. Smith
Executive Vice President, Chief Financial Officer
|
52 |
Since 2023
3 years
|
|
|
Jethro Ekuta
Chief Regulatory & Safety Officer
|
62 |
Since 2024
2 years
|
|
|
Sherrie Glass
Chief Business Officer
|
54 |
Since 2024
2 years
|
|
|
Michael Wolff Jensen
Executive Vice President, Chief Legal Officer
|
54 |
Since 2023
3 years
|
|
|
Lotte Sønderbjerg
Executive Vice President, Chief Administrative Officer
|
64 |
Since 2023
3 years
|
|
|
Aimee Shu
Executive Vice President, Chief Medical Officer
|
49 |
Since 2024
2 years
|
|
|
Anni Lotte Kirstine Sonderbjerg Pedersen
EVP & Chief Admin Officer
Title from the Form 3 dated Mar 18, 2026
|
Not stated | Not stated | |
|
Jay Donovan Wu
EVP & President US Market
Title from the Form 3 dated Mar 18, 2026
|
40 | Not stated | |
|
Stina Singel
Executive Vice President, Head of Clinical Development, Oncology
|
52 |
Since 2023
3 years
|
|
|
Mads Bodenhoff
SVP & PAO
Title from the Form 4 dated Sep 8, 2026
|
57 | Not stated | |
|
Flemming Steen Jensen
See Remarks
Title from the Form 4 dated May 11, 2026
|
64 | Not stated | |
|
Kennett Sprogøe
See Remarks
Title from the Form 3 dated Mar 18, 2026
|
47 | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Related-party transactions come from the company’s proxy statement. Ascendis Pharma A/S has not filed one with the SEC.
Loading...